Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR. Cohen SB, et al. Among authors: hendrickson b. Ann Rheum Dis. 2021 Mar;80(3):304-311. doi: 10.1136/annrheumdis-2020-218510. Epub 2020 Oct 28. Ann Rheum Dis. 2021. PMID: 33115760 Free PMC article. Clinical Trial.
Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Liang H, Danwada R, Guo D, Curtis JR, Kilpatrick RD, Hendrickson B, Islam SS. Liang H, et al. Among authors: hendrickson b. RMD Open. 2019 Sep 23;5(2):e001013. doi: 10.1136/rmdopen-2019-001013. eCollection 2019. RMD Open. 2019. PMID: 31673413 Free PMC article.
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI. Reich K, et al. Among authors: hendrickson ba. Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21. Lancet. 2021. PMID: 34023009 Clinical Trial.
Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study.
Winthrop K, Vargas JI, Drescher E, Garcia C, Friedman A, Hendrickson B, Li Y, Klaff J, Kivitz A. Winthrop K, et al. Among authors: hendrickson b. RMD Open. 2022 Mar;8(1):e002110. doi: 10.1136/rmdopen-2021-002110. RMD Open. 2022. PMID: 35246470 Free PMC article. Clinical Trial.
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, Chih-Ho Hong H, Hendrickson B, Dilley D, Tenorio AR, Ladizinski B, Chu AD, Liu J, Irvine AD. Guttman-Yassky E, et al. Among authors: hendrickson b. J Allergy Clin Immunol. 2023 Jan;151(1):172-181. doi: 10.1016/j.jaci.2022.09.023. Epub 2022 Oct 1. J Allergy Clin Immunol. 2023. PMID: 36195170 Free article.
Aggregate Safety Assessment Planning for the Drug Development Life-Cycle.
Hendrickson BA, Wang W, Ball G, Bennett D, Bhattacharyya A, Fries M, Kuebler J, Kurek R, McShea C, Tremmel L. Hendrickson BA, et al. Ther Innov Regul Sci. 2021 Jul;55(4):717-732. doi: 10.1007/s43441-021-00271-2. Epub 2021 Mar 23. Ther Innov Regul Sci. 2021. PMID: 33755928
103 results